Table 1.

Baseline patient and tumour characteristics

	AC-T (N = 100) %	TAC (N = 101) %
Age, years
Median	49	49
Range	27–70	24–68
Initial tumour status
cT1-cT2	51	50
cT3-4	49	50
Initial nodal status
cN0	24	26
cN+	76	74
Receptor status
HR+/HER2−	51	58
HR+/HER2+	15	8
HR−/HER2+	11	8
HR−/HER2−	23	27

A doxorubicin, C cyclophosphamide, T docetaxel, HR hormone receptor, HER2 human epidermal growth factor receptor 2